Refine Search

Search Results -

Term	Documents
5.CLM..PGPB,USPT.	0
(L5.CLM.).PGPB,USPT.	0

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L6

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Monday, April 03, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT; PLUR=YES; OP=ADJ			
L6	L5.clm.	0	L6
L5	(tgf$ or transforming adj growth)same (antibod$)same (nephritis or glomerulonephritis or diabetes)	195	L5
L4	(tgf$ or transforming adj growth)same (antibod$) and (nephritis or glomerulonephritis or diabetes)	1672	L4
L3	(L1 or L2) and (tgf$ or transforming adj growth)	21	L3
L2	ruoslahti.in.	99	L2
L1	border.in.	320	L1

END OF SEARCH HISTORY

Generate Collection Print

Search Results - Record(s) 1 through 10 of 21 returned.

☐ 1. 20050124534. 27 Sep 04. 09 Jun 05. Methods for treating conditions associated with the accumulation of excess extracellular matrix. Noble, Nancy A., et al. 514/8; 424/145.1 424/94.64 514/381 514/423 514/44 A61K048/00 A61K038/48 A61K039/395 A61K031/4178 A61K031/401.

☐ 2. 20050037007. 08 Jul 04. 17 Feb 05. Methods for treating conditions associated with the accumulation of excess extracellular matrix. Noble, Nancy A., et al. 424/145.1; 514/12 514/171 514/423 A61K039/395 A61K038/17 A61K031/56 A61K031/401.

☐ 3. 20040028682. 07 Aug 03. 12 Feb 04. Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix. Border, Wayne A., et al. 424/145.1; 514/18 A61K039/395.

☐ 4. 20030045476. 20 Jul 01. 06 Mar 03. Heart homing conjugates. Ruoslahti, Erkki, et al. 514/16; A61K038/08.

☐ 5. 20030032591. 21 Aug 01. 13 Feb 03. Inhibitors of cell regulatory factors and methods for preventing or reducing scarring. Ruoslahti, Erkki I., et al. 514/12; 514/54 A61K038/17 A61K031/728.

☐ 6. 6906026. 05 Jul 01; 14 Jun 05. Methods for treating conditions associated with the accumulation of excess extracellular matrix. Noble; Nancy A., et al. 514/2; 435/4 435/6 435/7.1 514/4 514/44. A61K048/00 A61K039/395 A61K038/00 .

☐ 7. 6509314. 13 Jun 94; 21 Jan 03. Methods of preventing or reducing scarring with decorin or biglycan. Ruoslahti; Erkki I., et al. 514/8; 514/2 530/350. A01N061/00 A61K038/17 .

☐ 8. 6436900. 02 Jun 95; 20 Aug 02. Methods of treating a pathology or a fibrotic condition by administering decorin. Ruoslahti; Erkki I., et al. 514/8; 514/12 514/2 530/350. A61K038/16 A61K038/02 A61K038/39 C07K014/435 .

☐ 9. 6316258. 15 Dec 98; 13 Nov 01. Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF.beta. using renin inhibitors. Noble; Nancy A., et al. 435/375; 435/7.1. G01N033/50 .

☐ 10. 6303573. 07 Jun 99; 16 Oct 01. Heart homing peptides and methods of using same. Ruoslahti; Erkki, et al. 514/12; 424/185.1 514/14 514/16 514/2 514/21 530/300 530/324 530/327 530/328 530/329. A61K038/00 .

Generate Collection Print

Term	Documents
TRANSFORMING	110260
TRANSFORMINGS	3
GROWTH	416460
GROWTHS	7043
TGF$	0

Generate Collection Print

Search Results - Record(s) 11 through 20 of 21 returned.

☐ 11. 6277812. 02 Jun 95; 21 Aug 01. Methods for inhibiting TGF-.beta. activity. Ruoslahti; Erkki I., et al. 514/2; 435/69.1 514/8 530/395. A01N061/00 .

☐ 12. 6046162. 02 Jun 95; 04 Apr 00. Suppression of cell proliferation by decorin. Ruoslahti; Erkki I., et al. 514/8; 514/2 530/350 530/395. A61K038/02 A61K038/16 A61K038/39 .

☐ 13. 5955578. 05 Jun 95; 21 Sep 99. Polypeptide-polymer conjugates active in wound healing. Pierschbacher; Michael D., et al. 530/345; 530/324 530/353 530/354 530/355 530/356 530/357 530/404 530/405 530/408 530/409. A61K038/00 .

☐ 14. 5830504. 01 Jun 95; 03 Nov 98. Cooperative combinations of ligands contained within a matrix. Vuori; Kristiina, et al. 424/484; 424/486 514/2 514/3. A61K038/04 A61K038/18 A61K038/20 A61K038/28 .

☐ 15. 5824655. 15 Feb 95; 20 Oct 98. Anti-transforming growth factor-.beta. gene therapy. Border; Wayne A.. 514/44; 424/93.21 424/93.7 435/320.1 435/352 435/353 435/354 435/366 514/2. A01N043/04 .

☐ 16. 5726149. 22 Jan 91; 10 Mar 98. Treatment of glomerulonephritis with decorin. Ruoslahti; Erkki I., et al. 514/8; 514/2 530/350 530/395. A61K038/02 A61K038/16 A61K038/39 .

☐ 17. 5705609. 16 May 95; 06 Jan 98. Decorin fragments inhibiting cell regulatory factors. Ruoslahti; Erkki I., et al. 530/329; 530/324 530/399 930/10. C07K007/06 C07K014/435 A61K038/08 A61K038/17 .

☐ 18. 5654270. 08 Sep 94; 05 Aug 97. Use of fibromodulin to prevent or reduce dermal scarring. Ruoslahti; Erkki I., et al. 514/8; 435/69.1 514/2. C07K014/435 A61K038/17 .

☐ 19. 5654267. 30 Nov 94; 05 Aug 97. Cooperative combinations of ligands contained within a matrix. Vuori; Kristiina, et al. 514/2; 424/488 514/12 514/13 514/3 530/303 530/326 530/351 530/380 530/399. A61K038/00 .

☐ 20. 5583103. 14 Mar 94; 10 Dec 96. Inhibition of transforming growth factor beta activity. Ruoslahti; Erkki I., et al. 514/8; 514/2 530/350 530/380 530/399. A61K038/19 C07K014/495 .

Generate Collection Print

Term	Documents
TRANSFORMING	110260
TRANSFORMINGS	3
GROWTH	416460
GROWTHS	7043
TGF$	0
TGF	15708

Generate Collection Print

Search Results - Record(s) 21 through 21 of 21 returned.

☐ 21. 5453492. 28 Jul 93; 26 Sep 95. 60 kDa transforming growth factor-.beta.-binding protein and its use to detect or purify TGF-.beta.. Butzow; Ralf, et al. 530/413; 435/7.1 530/350 530/395 530/402. C07K014/435 C07K001/22 G01N033/58 .

Generate Collection Print

Term	Documents
TRANSFORMING	110260
TRANSFORMINGS	3
GROWTH	416460
GROWTHS	7043
TGF$	0
TGF	15708
TGFA	246
TGFAABMB	3
TGFAB	2
TGFACIDS	1
TGFAIL	1
((L1 OR L2) AND (TGF$ OR TRANSFORMING ADJ GROWTH)).PGPB,USPT.	21

There are more results than shown above. Click here to view the entire set.

Prev Page Next Page Go to Doc#

First Hit Fwd Refs

L3: Entry 15 of 21 File: USPT Oct 20, 1998

US-PAT-NO: 5824655
DOCUMENT-IDENTIFIER: US 5824655 A

TITLE: Anti-transforming growth factor-.beta. gene therapy

DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Border; Wayne A.	Salt Lake City	UT		

US-CL-CURRENT: 514/44; 424/93.21, 424/93.7, 435/320.1, 435/352, 435/353, 435/354, 435/366, 514/2

CLAIMS:

I claim:

1. A method for reducing deleterious accumulation of TGF-.beta. induced extracellular matrix in tissue of a subject, said method comprising:

(a) introducing into the subject a heterologous nucleic acid encoding a TGF-.beta. inhibitory agent selected from the group consisting of a proteoglycan, a TGF-.beta. receptor, an anti-TGF-.beta. antibody, a fragment of the proteoglycan, a fragment of the TGF-.beta. receptor, and a fragment of the anti-TGF-.beta. antibody, where each agent has the TGF-.beta. inhibitory function of reducing deleterious accumulation of TGF-.beta. induced extracellular matrix; and

(b) expressing in cells in said subject the introduced nucleic acid encoding the TGF-.beta. inhibitory agent and secreting the TGF-.beta. inhibitory agent encoded by the introduced nucleic acid for a time and under conditions effective to produce an amount of the TGF-.beta. inhibitory agent effective to reduce the deleterious accumulation of extracellular matrix material in said tissue of a subject where deleterious accumulation of extracellular matrix material induced by TGF-.beta. occurs.

2. The method of claim 1, wherein said TGF-.beta. specific inhibitory agent is first introduced into a cell ex viva to obtain a cell expressing the TGF-.beta. specific inhibitory agent and the cell expressing said agent is transplanted into said subject.

3. The method of claim 1, wherein said cell is selected from the group consisting of a skeletal muscle cell, a kidney cell, a lung cell, a liver cell and a skin cell.

4. The method of claim 1, wherein said deleterious accumulation of extracellular matrix is associated with a condition in the subject selected from the group consisting of glomerulonephritis, ARDs, cirrhosis of the

livers, fibrotic cancer, fibrosis of the lungs, post myocardial infarction, cardiac fibrosis, post-angioplasty restinosis, renal interstitial fibrosis, scarring or a diabetes-associated pathology.

5. The method of claim 1, wherein said tissue is selected from the group consisting of kidney, liver, lung and skin tissue.

6. A method for reducing the accumulation of extracellular matrix associated with glomerulonephritis in a subject comprising:

a) introducing into the subject a heterologous nucleic acid encoding a TGF-.beta. inhibitory agent selected from the group consisting of a proteoglycan, a TGF-.beta. receptor, an anti-TGF-.beta. antibody, a fragment of the proteoglycan, a fragment of the TGF-.beta. receptor, and a fragment of the anti-TGF.beta. antibody, where each agent has the TGF-.beta. inhibitory function of reducing deleterious accumulation of TGF-.beta. induced extracellular matrix; and

(b) expressing in cells in said subject the introduced nucleic acid encoding the TGF-.beta. inhibitory agent and secreting the TGF-.beta. inhibitory agent encoded by the introduced nucleic acid for a time and under conditions effective to produce an amount of the TGF-.beta. inhibitory agent effective to reduce accumulation of extracellular matrix material induced by TGF-.beta. in the kidney and suppress glomerulonephritis.

7. The method of claim 1 or claim 6, wherein said TGF-.beta. specific inhibitory agent is selected from the group consisting of decorin, biglycan, fibromodulin, lumican, betaglycan and endoglin, and fragments thereof having TGF-.beta. inhibitory action.